{"id":11906,"date":"2025-09-17T10:52:37","date_gmt":"2025-09-17T10:52:37","guid":{"rendered":"https:\/\/sarms-direct.com\/?page_id=11906"},"modified":"2026-04-07T11:42:44","modified_gmt":"2026-04-07T11:42:44","slug":"orforglipron-wholesale-bulk-supply-research-use-only","status":"publish","type":"page","link":"https:\/\/sarms-direct.com\/pt\/orforglipron-wholesale-bulk-supply-research-use-only\/","title":{"rendered":"Orforglipron \u2013 Wholesale & Bulk Supply (Research Use Only)"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"11906\" class=\"elementor elementor-11906\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-a9f5125 e-flex e-con-boxed e-con e-parent\" data-id=\"a9f5125\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-b2c49ce elementor-widget elementor-widget-html\" data-id=\"b2c49ce\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<section class=\"content-section hero\">\r\n  <h1>Orforglipron \u2013 Wholesale & Bulk Supply (Research Use Only)<\/h1>\r\n  <p class=\"subheading\">\r\n    Orforglipron (LY3502970) is a <strong>non-peptide, oral GLP-1 receptor agonist<\/strong> in late-stage clinical development. \r\n    Ideal for obesity and type 2 diabetes research programs seeking an oral small-molecule alternative to injectables.\r\n  <\/p>\r\n  <div class=\"cta-block\">\r\n    <a href=\"#quote\" class=\"btn\">Request Bulk Pricing<\/a>\r\n    <a href=\"#specs\" class=\"btn alt\">Specifications<\/a>\r\n  <\/div>\r\n  <p class=\"mini\">\r\n    B2B supply for CROs, universities, and pharmaceutical developers \u2022 Global shipping \u2022 COA on request\r\n  <\/p>\r\n<\/section>\r\n\r\n<section class=\"content-section alt\">\r\n  <h2>Key Highlights<\/h2>\r\n  <div class=\"quality-block\">\r\n    <ul>\r\n      <li><strong>Small-Molecule, Oral:<\/strong> Once-daily tablet format; no cold chain required\u2014streamlines logistics and scale-up studies.<\/li>\r\n      <li><strong>GLP-1 Agonist:<\/strong> Targets GLP-1 receptor; supports weight-management and glycemic-control research endpoints.<\/li>\r\n      <li><strong>Late-Stage Development:<\/strong> Ongoing Phase III programs in obesity and type 2 diabetes research contexts.<\/li>\r\n    <\/ul>\r\n  <\/div>\r\n<\/section>\r\n\r\n<section class=\"content-section\">\r\n  <h2>Product Overview<\/h2>\r\n  <p>\r\n    Orforglipron (LY3502970) is a first-in-class <strong>oral GLP-1 receptor agonist<\/strong> developed for once-daily dosing. \r\n    Unlike peptide GLP-1s (e.g., semaglutide, tirzepatide), orforglipron\u2019s small-molecule design supports oral administration and simplified handling. \r\n    It is currently an <strong>investigational compound<\/strong> and is available strictly for <strong>laboratory research use only<\/strong>.\r\n  <\/p>\r\n<\/section>\r\n\r\n<section class=\"content-section alt\" id=\"specs\">\r\n  <h2>Technical Specifications<\/h2>\r\n  <table class=\"table\">\r\n    <tbody>\r\n      <tr><th>Compound<\/th><td>Orforglipron (LY3502970)<\/td><\/tr>\r\n      <tr><th>Type<\/th><td>Non-peptide GLP-1 receptor agonist<\/td><\/tr>\r\n      <tr><th>Form<\/th><td>Oral small molecule (tablet \/ powder for R&amp;D workflows)<\/td><\/tr>\r\n      <tr><th>Status<\/th><td>Investigational (Research Use Only; not for human consumption)<\/td><\/tr>\r\n      <tr><th>Applications<\/th><td>Obesity pharmacotherapy research; Type 2 diabetes R&amp;D; metabolic studies<\/td><\/tr>\r\n      <tr><th>Documentation<\/th><td>COA on request; batch traceability available<\/td><\/tr>\r\n      <tr><th>MOQ<\/th><td>Flexible (inquire for pilot vs scale)<\/td><\/tr>\r\n      <tr><th>Packaging<\/th><td>Research-grade bulk packaging; tamper-evident seals<\/td><\/tr>\r\n    <\/tbody>\r\n  <\/table>\r\n<\/section>\r\n\r\n<section class=\"content-section\">\r\n  <h2>Scientific Summary<\/h2>\r\n  <ul>\r\n    <li><strong>Weight-management outcomes:<\/strong> Late-stage studies report double-digit mean weight reduction at higher doses in non-diabetic cohorts.<\/li>\r\n    <li><strong>Glycemic control:<\/strong> HbA1c reductions reported in type 2 diabetes research populations.<\/li>\r\n    <li><strong>Tolerability:<\/strong> Predominantly GI-related AEs typical of GLP-1 class (nausea, diarrhea, constipation) in trials.<\/li>\r\n    <li><strong>Operational advantages:<\/strong> Oral dosing removes cold-chain constraints, aiding multi-site or decentralized designs.<\/li>\r\n  <\/ul>\r\n  <p class=\"note\">\r\n    Note: Orforglipron remains investigational. All statements pertain to research contexts and public trial data. \r\n    No claims of safety or efficacy are made for clinical or consumer use.\r\n  <\/p>\r\n<\/section>\r\n\r\n<section class=\"content-section alt\">\r\n  <h2>Orforglipron vs Other GLP-1 Pathway Agents<\/h2>\r\n  <table class=\"table\">\r\n    <thead>\r\n      <tr>\r\n        <th>Compound<\/th>\r\n        <th>Form<\/th>\r\n        <th>Mechanism<\/th>\r\n        <th>Typical Weight-Loss (Research)<\/th>\r\n        <th>Status<\/th>\r\n      <\/tr>\r\n    <\/thead>\r\n    <tbody>\r\n      <tr>\r\n        <td><strong>Orforglipron<\/strong><\/td>\r\n        <td>Oral (daily)<\/td>\r\n        <td>GLP-1 agonist<\/td>\r\n        <td>~Double-digit mean reduction at higher doses*<\/td>\r\n        <td>Phase III<\/td>\r\n      <\/tr>\r\n      <tr>\r\n        <td>Semaglutide<\/td>\r\n        <td>Weekly injection<\/td>\r\n        <td>GLP-1 agonist<\/td>\r\n        <td>~15\u201317% (dose-dependent)<\/td>\r\n        <td>Approved<\/td>\r\n      <\/tr>\r\n      <tr>\r\n        <td>Tirzepatide<\/td>\r\n        <td>Weekly injection<\/td>\r\n        <td>GLP-1 + GIP dual agonist<\/td>\r\n        <td>~20%+<\/td>\r\n        <td>Approved<\/td>\r\n      <\/tr>\r\n      <tr>\r\n        <td>Retatrutide<\/td>\r\n        <td>Weekly injection<\/td>\r\n        <td>GLP-1 + GIP + Glucagon (triple)<\/td>\r\n        <td>~24%+ (Phase II data)<\/td>\r\n        <td>Phase II\/III<\/td>\r\n      <\/tr>\r\n    <\/tbody>\r\n  <\/table>\r\n  <p class=\"mini\">*Aggregated from publicly reported trial readouts; not directly comparable across studies.<\/p>\r\n  <p class=\"interlinks\">\r\n    See also: \r\n    <a href=\"\/#\/semaglutide-wholesale\">Semaglutide Wholesale<\/a> \u2022 \r\n    <a href=\"\/#\/tirzepatide-wholesale\">Tirzepatide Wholesale<\/a> \u2022 \r\n    <a href=\"\/#\/retatrutide-research\">Retatrutide (Research)<\/a>\r\n  <\/p>\r\n<\/section>\r\n\r\n<section class=\"content-section\">\r\n  <h2>Wholesale &amp; Logistics<\/h2>\r\n  <div class=\"quality-block\">\r\n    <h3>Supply Options<\/h3>\r\n    <ul>\r\n      <li>Pilot and scale quantities for R&amp;D environments<\/li>\r\n      <li>Global shipping with compliant paperwork<\/li>\r\n      <li>Batch COA and QC documentation<\/li>\r\n      <li>Secure, serialized packaging<\/li>\r\n    <\/ul>\r\n  <\/div>\r\n  <div class=\"quality-block\">\r\n    <h3>Buyer Eligibility<\/h3>\r\n    <ul>\r\n      <li>CROs, universities, pharma R&amp;D groups<\/li>\r\n      <li>Qualified B2B distributors and labs<\/li>\r\n      <li>Not sold to consumers; not for clinical use<\/li>\r\n    <\/ul>\r\n  <\/div>\r\n<\/section>\r\n\r\n<section class=\"content-section alt\">\r\n  <h2>Safety &amp; Legal Notice<\/h2>\r\n  <p>\r\n    Orforglipron is an <strong>investigational research compound<\/strong>. \r\n    <strong>Not for human consumption<\/strong>, medical treatment, or clinical use. \r\n    Purchases are restricted to qualified institutional or professional buyers.\r\n  <\/p>\r\n<\/section>\r\n\r\n<section class=\"content-section\" id=\"quote\">\r\n  <h2>Request a Quote<\/h2>\r\n  <p>Tell us your target quantity, delivery location, and documentation needs. Our B2B team will respond within one business day.<\/p>\r\n\r\n  <p class=\"contact-mini\">\r\n    Prefer direct? Whatsapp +44 7880 485232 or email <a href=\"mailto:info@sarms-direct.com\">info@sarmsdirect.com<\/a>.\r\n  <\/p>\r\n<\/section>\r\n\r\n<section class=\"content-section alt\">\r\n  <h2>Orforglipron \u2013 Frequently Asked Questions<\/h2>\r\n  <div class=\"faq\">\r\n    <h3>Is orforglipron available for consumer use?<\/h3>\r\n    <p>No. It is an investigational compound for research use only.<\/p>\r\n\r\n    <h3>Do you supply COAs?<\/h3>\r\n    <p>Yes. Batch COAs and QC documentation are available on request for qualified buyers.<\/p>\r\n\r\n    <h3>What are typical research endpoints?<\/h3>\r\n    <p>Weight-management and glycemic-control outcomes (e.g., body-weight change, HbA1c, metabolic markers), per protocol.<\/p>\r\n\r\n    <h3>Can you white-label or support formulation work?<\/h3>\r\n    <p>Yes, for eligible B2B partners we can discuss white-label and formulation support for R&amp;D contexts.<\/p>\r\n  <\/div>\r\n<\/section>\r\n\r\n<style>\r\n  .content-section {\r\n    max-width: 900px;\r\n    margin: 0 auto;\r\n    padding: 40px 20px;\r\n    font-family: Arial, sans-serif;\r\n  }\r\n\r\n  .content-section.alt {\r\n    background: #fafafa;\r\n  }\r\n\r\n  .content-section h1 {\r\n    font-size: 32px;\r\n    margin-bottom: 15px;\r\n    color: #111;\r\n  }\r\n\r\n  .content-section h2 {\r\n    font-size: 28px;\r\n    margin-bottom: 20px;\r\n    color: #111;\r\n  }\r\n\r\n  .content-section .subheading {\r\n    font-size: 18px;\r\n    color: #00b0ff;\r\n    margin-bottom: 25px;\r\n  }\r\n\r\n  .content-section p {\r\n    line-height: 1.7;\r\n    margin-bottom: 20px;\r\n  }\r\n\r\n  .quality-block {\r\n    margin-bottom: 30px;\r\n  }\r\n\r\n  .quality-block h3 {\r\n    color: #00b0ff;\r\n    font-size: 20px;\r\n    margin-bottom: 12px;\r\n  }\r\n\r\n  .quality-block ul {\r\n    list-style: disc;\r\n    padding-left: 20px;\r\n  }\r\n\r\n  .quality-block li {\r\n    margin-bottom: 8px;\r\n  }\r\n\r\n  .table {\r\n    width: 100%;\r\n    border-collapse: collapse;\r\n    margin-bottom: 20px;\r\n  }\r\n\r\n  .table th, .table td {\r\n    border: 1px solid #eee;\r\n    padding: 12px;\r\n    text-align: left;\r\n  }\r\n\r\n  .cta-block {\r\n    margin: 20px 0;\r\n  }\r\n\r\n  .btn {\r\n    background-color: #00b0ff;\r\n    color: white;\r\n    padding: 12px 25px;\r\n    text-decoration: none;\r\n    border-radius: 5px;\r\n    margin: 0 10px 10px 0;\r\n    display: inline-block;\r\n    transition: background 0.3s ease;\r\n  }\r\n\r\n  .btn:hover {\r\n    background-color: #0091d3;\r\n  }\r\n\r\n  .btn.alt {\r\n    background-color: transparent;\r\n    color: #00b0ff;\r\n    border: 2px solid #00b0ff;\r\n  }\r\n\r\n  .btn.alt:hover {\r\n    background-color: #00b0ff;\r\n    color: #fff;\r\n  }\r\n\r\n  .mini, .note, .contact-mini {\r\n    font-size: 0.9rem;\r\n    color: #666;\r\n  }\r\n<\/style>\r\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Orforglipron \u2013 Wholesale &#038; Bulk Supply (Research Use Only) Orforglipron (LY3502970) is a non-peptide, oral GLP-1 receptor agonist in late-stage clinical development. Ideal for obesity and type 2 diabetes research programs seeking an oral small-molecule alternative to injectables. Request Bulk Pricing Specifications B2B supply for CROs, universities, and pharmaceutical developers \u2022 Global shipping \u2022 COA&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-11906","page","type-page","status-publish","hentry"],"brizy_media":[],"_links":{"self":[{"href":"https:\/\/sarms-direct.com\/pt\/wp-json\/wp\/v2\/pages\/11906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sarms-direct.com\/pt\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sarms-direct.com\/pt\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sarms-direct.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/sarms-direct.com\/pt\/wp-json\/wp\/v2\/comments?post=11906"}],"version-history":[{"count":5,"href":"https:\/\/sarms-direct.com\/pt\/wp-json\/wp\/v2\/pages\/11906\/revisions"}],"predecessor-version":[{"id":11918,"href":"https:\/\/sarms-direct.com\/pt\/wp-json\/wp\/v2\/pages\/11906\/revisions\/11918"}],"wp:attachment":[{"href":"https:\/\/sarms-direct.com\/pt\/wp-json\/wp\/v2\/media?parent=11906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}